Viridian Therapeutics (VRDN) News Today $11.78 -0.21 (-1.75%) Closing price 04:00 PM EasternExtended Trading$11.78 0.00 (-0.04%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsApril 7 at 7:37 AM | finance.yahoo.comAlliancebernstein L.P. Buys 84,255 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Alliancebernstein L.P. lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 3.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,286,994 shares of the company's stock after acquiring an additional 84,255April 7 at 4:12 AM | marketbeat.comBryce Point Capital LLC Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Bryce Point Capital LLC bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 44,063 shares of the company's stock, valued at approApril 5 at 5:39 AM | marketbeat.com25,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Bought by Knott David M JrKnott David M Jr bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company's stock, valued at approximately $47April 2, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Pictet Asset Management Holding SA increased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 21.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,248,721 shares of the company's stocApril 2, 2025 | marketbeat.comLoomis Sayles & Co. L P Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Loomis Sayles & Co. L P acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,400,381 shares of the company's stock, valued at apMarch 29, 2025 | marketbeat.comBIT Capital GmbH Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)BIT Capital GmbH boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 239.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 285,954 shares of the company's stoMarch 28, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Raymond James Financial Inc. purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 313,787 shares of the company's stock, valued at approximately $6,015,000. Raymond James FinanciaMarch 25, 2025 | marketbeat.comCommit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using OptionsMarch 22, 2025 | nasdaq.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Yiheng Capital Management L.P.Yiheng Capital Management L.P. trimmed its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750,261 shares of the comMarch 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Charles Schwab Investment Management Inc. boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 575,070 shares of the company's stock after buying an additioMarch 22, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have givenMarch 20, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 196,522 shares of the companyMarch 19, 2025 | marketbeat.com410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc.Victory Capital Management Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 410,440 shares of the company'sMarch 15, 2025 | marketbeat.comViridian Therapeutics appoints new director, sees board resignationMarch 12, 2025 | investing.comCandriam S.C.A. Has $14.02 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Candriam S.C.A. decreased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 731,221 shares of the company's stock after selling 18,583 sharMarch 7, 2025 | marketbeat.comResearch Analysts Issue Forecasts for VRDN Q1 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will earnMarch 6, 2025 | marketbeat.comFisher Asset Management LLC Acquires 23,103 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Fisher Asset Management LLC lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,027 shares of the company's stock after purchasinMarch 5, 2025 | marketbeat.comQ2 Earnings Forecast for VRDN Issued By B. RileyViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at B. Riley issued their Q2 2025 EPS estimates for shares of Viridian Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.14) per sMarch 4, 2025 | marketbeat.comViridian Therapeutics Faces Uncertainty Amid Regulatory Approval ChallengesMarch 4, 2025 | tipranks.comWhat is Leerink Partnrs' Forecast for VRDN FY2029 Earnings?Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Leerink Partnrs dropped their FY2029 earnings per share estimates for shares of Viridian Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now forecasts that the coMarch 3, 2025 | marketbeat.comQ1 EPS Estimates for Viridian Therapeutics Raised by WedbushViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Wedbush increased their Q1 2025 earnings per share estimates for shares of Viridian Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst L. Chico now anticipates that the company willMarch 3, 2025 | marketbeat.comViridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year WindowMarch 2, 2025 | seekingalpha.comWedbush Reduces Earnings Estimates for Viridian TherapeuticsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Wedbush lowered their FY2027 earnings estimates for Viridian Therapeutics in a report issued on Thursday, February 27th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $3.77March 1, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPSViridian Therapeutics (NASDAQ:VRDN - Get Free Report) issued its earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.February 28, 2025 | marketbeat.comViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | businesswire.comRice Hall James & Associates LLC Invests $1.02 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Rice Hall James & Associates LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 53,375 shares of the company's stock, valued at approximatelyFebruary 19, 2025 | marketbeat.comViridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on TuesdayViridian Therapeutics (NASDAQ:VRDN) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 5% - Here's WhyViridian Therapeutics (NASDAQ:VRDN) Trading Down 5% - Here's WhyFebruary 12, 2025 | marketbeat.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | businesswire.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8% - What's Next?Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% - Should You Sell?February 5, 2025 | marketbeat.comSG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)SG Americas Securities LLC lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 89.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,085 shares of the company's stoJanuary 31, 2025 | marketbeat.comShort Interest in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Grows By 28.9%Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 12,050,000 shares, an increase of 28.9% from the December 31st total of 9,350,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is currently 9.3 days.January 30, 2025 | marketbeat.comMoody Aldrich Partners LLC Takes $1.13 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Moody Aldrich Partners LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 58,688 shares of the company'sJanuary 30, 2025 | marketbeat.comEquities Analysts Issue Forecasts for VRDN Q1 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Viridian Therapeutics in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post eaJanuary 29, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation aJanuary 29, 2025 | marketbeat.comViridian Therapeutics Primed for Market Domination with Promising Veligrotug Results and Strategic PositioningJanuary 28, 2025 | markets.businessinsider.comLeerink Partnrs Weighs in on VRDN FY2029 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst T. SmitJanuary 28, 2025 | marketbeat.comViridian Metals becomes top claim holder in Newfoundland and LabradorJanuary 24, 2025 | msn.comViridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3% - What's Next?Viridian Therapeutics (NASDAQ:VRDN) Shares Up 6.3% - Time to Buy?January 17, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest Up 28.9% in DecemberViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 12,050,000 shares, an increase of 28.9% from the December 15th total of 9,350,000 shares. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is presently 9.3 days.January 16, 2025 | marketbeat.comViridian Therapeutics: Promising Market Position with Superior Efficacy and Safety of Veligrotug in TED TreatmentJanuary 15, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)JPMorgan Chase & Co. boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 218.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 400,351 shares of the company's stock after purJanuary 14, 2025 | marketbeat.comViridian Therapeutics: Strategic Positioning and First-Mover Advantage in the TED MarketJanuary 9, 2025 | markets.businessinsider.comViridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye DiseaseJanuary 8, 2025 | finance.yahoo.comViridian Therapeutics: Strategic Positioning and Promising Data Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comViridian Therapeutics: Promising Pipeline and Strong Financials Justify Buy RatingJanuary 7, 2025 | markets.businessinsider.comPositive Outlook for Viridian Therapeutics: Analyst Reaffirms Buy Rating on Strong Competitive Position and Efficacy of VRDN-001January 7, 2025 | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8% - Here's WhyViridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8% - Should You Buy?January 7, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday.January 7, 2025 | marketbeat.com Remove Ads Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼1.390.64▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼54▲VRDN Articles Average Week Remove Ads Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDNT News Today SHC News Today BTSG News Today SGRY News Today CON News Today PRVA News Today LFST News Today WGS News Today VCYT News Today ARDT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRDN Stock Free VRDN Stock Alerts